Munich Startup
EpiCure

EpiCure

EpiCure is a research project of Ludwig Maximilians University Munich and is scheduled to be incorporated as an independent biotech company in 2026/2027. The focus is on epigenetic therapies, a mechanism of action that still holds...

Founded2026
Business ModelB2B
IndustryBioTech
This content was machine translated.

About EpiCure

EpiCure is a research project of Ludwig Maximilians University Munich and is scheduled to be incorporated as an independent biotech company in 2026/2027. The focus is on epigenetic therapies, a mechanism of action that still holds considerable untapped potential in oncology. The lead compound is Carbacitabin (CAB), a drug molecule rationally designed on the basis of epigenetic expertise for blood cancer diseases, primarily positioned for high-risk patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). CAB was specifically developed to address the weaknesses of clinically used standard therapeutics, and achieves approximately 100-fold reduced toxicity in patient-derived tumor models while simultaneously demonstrating superior efficacy. The regulatory foundation is in place: The BfArM has confirmed the preclinical development program in Scientific Advice. The first clinical trial is planned for 2027/28.

More like this

Discover more articles, startups, and events from the ecosystem

From the Lab to a Startup: Why Good Research Alone Is Not Enough
Ecosystem

From the Lab to a Startup: Why Good Research Alone Is Not Enough

20.08.26
10 Min.
Science4Life Venture Cup: Epicure among top 5 startups
Ecosystem

Science4Life Venture Cup: Epicure among top 5 startups

03.12.24
3 Min.
Munich Startup Recap 39/26
Ecosystem

Munich Startup Recap 39/26

27.09.26
2 Min.